We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+34.73%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$612M
AUM Growth
+$82.6M
Cap. Flow
+$22.2M
Cap. Flow %
3.63%
Top 10 Hldgs %
69.92%
Holding
102
New
27
Increased
15
Reduced
11
Closed
43

Top Buys

Rank Stock Value
1
GYRE icon
Gyre Therapeutics
GYRE
+$17.5M
2
ARWR icon
Arrowhead Research
ARWR
+$10.9M
3
ARGX icon
argenx
ARGX
+$6.1M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.71M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.57M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$14.7M
2
ZGNX
Zogenix, Inc.
ZGNX
+$12M
3
PDSB icon
PDS Biotechnology
PDSB
+$8.84M
4
EVH icon
Evolent Health
EVH
+$5.17M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 61.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$85.5M 13.96%
5,850,000
-900,000
-13% -$14.7M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$1.93B
$72M 11.76%
4,260,000
+368,000
+9% +$5.57M
ASMB icon
3
Assembly Biosciences
ASMB
$503M
$54.8M 8.95%
92,917
+2,325
+3% +$1.44M
XBI icon
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$43.9M 7.16%
500,000
+150,000
+43% +$13.7M
ASND icon
5
Ascendis Pharma A/S
ASND
$16B
$35.6M 5.81%
544,000
+13,000
+2% +$731K
ARGX icon
6
argenx
ARGX
$52B
$32.5M 5.31%
403,821
+80,821
+25% +$6.1M
IWM icon
7
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$30.4M 4.96%
200,000
-50,000
-20% -$7.72M
GYRE icon
8
Gyre Therapeutics
GYRE
$681M
$29.8M 4.87%
153,963
+93,963
+157% +$17.5M
KDMN
9
DELISTED
Kadmon Holdings, Inc.
KDMN
$25.3M 4.13%
5,950,000
+1,035,000
+21% +$4.43M
VCYT icon
10
Veracyte
VCYT
$3.58B
$18.4M 3.01%
3,318,000
+22,889
+0.7% +$142K
INDP icon
11
Indaptus Therapeutics
INDP
$175M
$17.2M 2.81%
1,216
– –
CEMI
12
DELISTED
Chembio diagnostics, Inc.
CEMI
$16.1M 2.62%
2,006,667
+285,368
+17% +$2.28M
QQQ icon
13
PUT
Invesco QQQ Trust
QQQ
$469B
$13.6M 2.22%
+85,000
New +$14M
ARWR icon
14
Arrowhead Research
ARWR
$12.1B
$12.7M 2.08%
+1,762,206
New +$10.9M
VRAY
15
DELISTED
ViewRay, Inc.
VRAY
$11.9M 1.95%
1,852,878
-62,776
-3% -$523K
IRIX icon
16
IRIDEX
IRIX
$14.4M
$11.4M 1.87%
2,000,000
– –
ASMB icon
17
CALL
Assembly Biosciences
ASMB
$503M
$7.62M 1.24%
+12,917
New +$8.01M
AVXS
18
DELISTED
AveXis, Inc. Common Stock
AVXS
$7.42M 1.21%
60,000
+7,100
+13% +$844K
TNDM icon
19
Tandem Diabetes Care
TNDM
$1.38B
$6.68M 1.09%
+1,346,360
New +$4.34M
CASM
20
DELISTED
CAS Medical Systems, Inc.
CASM
$6.57M 1.07%
5,216,998
+56,998
+1% +$64.3K
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$372M
$6.56M 1.07%
+350,000
New +$5.71M
LLY icon
22
PUT
Eli Lilly
LLY
$1,000B
$5.8M 0.95%
+75,000
New +$6.04M
EEM icon
23
PUT
iShares MSCI Emerging Markets ETF
EEM
$28.9B
$4.83M 0.79%
+100,000
New +$4.9M
FXI icon
24
PUT
iShares China Large-Cap ETF
FXI
$4.35B
$3.54M 0.58%
75,000
-25,000
-25% -$1.23M
CUTR
25
DELISTED
Cutera, Inc.
CUTR
$3.52M 0.57%
+70,000
New +$3.42M
1
2 3 4 5

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Acuta Capital Partners held 102 positions worth $612M, up 16% from $530M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Acuta Capital Partners deployed $22.2M of net new capital in Q1 2018, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Arrowhead Research: 1,762,206 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 52% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $14.7M trimmed.

  • Acuta Capital Partners's largest Q1 2018 buy was Arrowhead Research: 1,762,206 shares worth $12.7M.
  • Acuta Capital Partners added most to Gyre Therapeutics in Q1 2018, an estimated $17.5M increase.
  • Acuta Capital Partners's biggest Q1 2018 reduction was Immunomedics Inc, cutting an estimated $14.7M.
  • Acuta Capital Partners fully exited Zogenix, Inc. in Q1 2018, selling an estimated $12M.
  • Acuta Capital Partners's ten largest holdings make up 70% of its $612M portfolio in Q1 2018.
  • Acuta Capital Partners opened 27 new positions and closed 43 in Q1 2018.
  • Acuta Capital Partners's portfolio value rose 16% quarter-over-quarter to $612M.

Based on Acuta Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.